Alzheimer’s disease is characterized by the presence of amyloid plaques in the patient’s brain. These plaques sequester copper, and contain approximately five times as much as a healthy brain.
Two CNRS scientists from the Coordination Chemistry Laboratory recently developed, with their colleagues from the Guangdong University of Technology and Shenzhen University (China), a molecule that regulates the circulation of copper in the brain.
The molecule extracts the copper trapped in amyloid plaques, and reintroduces it in the brain’s normal enzymatic circuit (which needs copper to function). Administered orally to an Alzheimer’s mouse model, this molecule inhibits memory loss among sick mice.
These results, which were published in ACS Chemical Neuroscience, open a new therapeutic avenue that could prove effective in early stages of Alzheimer’s disease among humans. The scientists are now seeking a pharmaceutical partner to develop preclinical trials for this drug candidate.
Jie Zhao et al. TDMQ20, a Specific Copper Chelator, Reduces Memory Impairments in Alzheimer’s Disease Mouse Models, ACS Chemical Neuroscience (2020). DOI: 10.1021/acschemneuro.0c00621
Regulating copper in the brain stops memory loss in a mouse model of Alzheimer’s (2020, December 17)
retrieved 17 December 2020
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.